Trial Profile
Erlotinib in Combination With Cisplatin as Radiosensitizing Agents in Women Receiving Radiation Therapy for Locally Advanced Squamous Cell Carcinoma of the Cervix; A Phase I Trial.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Cisplatin
- Indications Cervical cancer
- Focus Adverse reactions
- 15 May 2008 Status change from in progress to discontiuned, as reported on clinicaltrials.gov
- 06 Feb 2008 Status changed from recruiting to in progress.
- 11 Apr 2007 Status changed from initiated to recruiting